Read preview of all news stories
Audentes~Genethon Announce Their Agreement To Develop Treatment For Patients Affected By X-Linked Myotubular Myopathy
Press release today, 5th February 2012
Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X-Linked Myotubular Myopathy
Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non-profit organization dedicated to the research and development of biotherapies for orphan genetic diseases, announce that they have entered into an agreement to develop AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), a rare, inherited disorder characterized by severe muscle weakness and respiratory impairment. AT001 is a novel drug candidate based on adeno-associated virus (AAV) gene therapy technology.
“Our agreement with Genethon is a significant step forward towards the development of a treatment for patients with this serious, rare disease,” said Matthew R. Patterson, President and CEO of Audentes. “The combination of Genethon’s expertise in the manufacturing and development of gene therapy products and Audentes’ world-class orphan drug development team will allow us to rapidly advance this program.”
The development of a potential treatment for XLMTM using gene therapy technology was initiated at Genethon in 2009. Studies by Buj-Bello et al in a mouse model of the disease demonstrated that delivery of the deficient gene using an AAV vector system resulted in increased expression of the protein, improvement in muscle architecture, reversal of muscle hypotrophy, improvement in muscle strength, and an improvement in overall survival (Buj-Bello et al, Human Molecular Genetics, 2008, Vol. 17: 213 2143; Buj-Bello et al, Molecular Therapy, 2013, 21:sup 1, S14). More recently, collaborators at Genethon, the University of Washington and Harvard University announced promising results from studies of the same treatment approach in a naturally occurring dog model of XLMTM (Childers et al., Science Translational Medicine, 22 January 2014 6:220ra10). These studies demonstrated that treatment with a single dose of AAV carrying the gene deficient in XLMTM resulted in an increase in muscle strength, improved respiratory function, and prolonged survival. These data are the first demonstration of persistent disease correction in a large animal model of a neuromuscular disease through the delivery of a single, intravenous administration of AAV.
“We are proud of our initial research on this important potential treatment for XLMTM and are very encouraged by the recently published data,” explained Frédéric Revah, Chief Executive Officer of Genethon. “We are confident that this collaboration with the experienced team at Audentes will help us achieve our goal of bringing a treatment to patients as soon as possible.”
For more information regarding Genethon, please visit www.genethon.fr.
About Audentes Therapeutics
For more information regarding Audentes, please visit www.audentestx.com.
Audentes and Genethon will be at the 2014 Myotubular Trust Family Conference held in London, to help answer any questions. You can pre-register to join us for our Family Conference on 12th July here.